Higher expression of A‑kinase anchoring‑protein 1 predicts poor prognosis in human hepatocellular carcinoma

Yu,Jian; Zhang,Yu; Zhou,Dongxun; Wu,Jun; Luo,Rong

doi:10.3892/ol.2018.8685

Higher expression of A‑kinase anchoring‑protein 1 predicts poor prognosis in human hepatocellular carcinoma

Authors:
- Jian Yu
- Yu Zhang
- Dongxun Zhou
- Jun Wu
- Rong Luo
View Affiliations

Affiliations: Department of Endocrinology, CHC International Hospital, Cixi, Zhejiang 315315, P.R. China, Department of Oncology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, Hubei 441000, P.R. China, Department of Endoscopy, Eastern Hepato‑biliary Surgery Hospital, Shanghai 200438, P.R. China
Published online on: May 10, 2018 https://doi.org/10.3892/ol.2018.8685
Pages: 131-136
Copyright: © Yu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

A‑kinase anchoring protein 1 (AKAP1) plays important regulatory roles in the regulation of mitochondrial function, oxidative metabolism, and cell survival. However, the expression pattern and prognostic value of AKAP1 in hepatocellular carcinoma (HCC) remains unclear. AKAP1 expression levels in tumor and matched non‑tumor tissues were evaluated using reverse transcription‑quantitative polymerase chain reaction and immunohistochemical staining. Kaplan‑Meier and Cox regression analyses were used to analyze the survival rates. We found that AKAP1 protein expression was increased in HCC tissues, and high AKAP1 expression was associated with tumor size (P=0.024), Tumor‑Node‑Metastasis stage (P=0.0296) and portal vein thrombosis (P=0.00498). Kaplan‑Meier survival analyses further revealed that high AKAP1 expression was associated with poor overall (P=0.004) and disease‑free survival (DFS) (P=0.002) rates in patients with HCC. Multivariate survival analysis revealed that AKAP1 served as an independent poor prognostic factor for DFS rates. The findings of the present study indicated that AKAP1 expression may contribute to HCC progression. High AKAP1 expression could serve as a valuable prognostic biomarker in predicting the survival of patients with HCC following radical resection.

View Figures

View References

1	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar : PubMed/NCBI
2	Bertuccio P, Turati F, Carioli G, Rodriguez T, La Vecchia C, Malvezzi M and Negri E: Global trends and predictions in hepatocellular carcinoma mortality. J Hepatol. 67:302–309. 2017. View Article : Google Scholar : PubMed/NCBI
3	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
4	Sharma SA, Kowgier M, Hansen BE, Brouwer WP, Maan R, Wong D, Shah H, Khalili K, Yim C, Heathcote EJ, et al: Toronto HCC risk index: A validated scoring system to predict 10-year risk of HCC in patients with cirrhosis. J Hepatol: S0168-8278(17)32248-1. 2017.
5	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
6	Fu J and Wang H: Precision diagnosis and treatment of liver cancer in China. Cancer Lett. 412:283–288. 2018. View Article : Google Scholar : PubMed/NCBI
7	Carlucci A, Adornetto A, Scorziello A, Viggiano D, Foca M, Cuomo O, Annunziato L, Gottesman M and Feliciello A: Proteolysis of AKAP121 regulates mitochondrial activity during cellular hypoxia and brain ischaemia. EMBO J. 27:1073–1084. 2008. View Article : Google Scholar : PubMed/NCBI
8	Czachor A, Failla A, Lockey R and Kolliputi N: Pivotal role of AKAP121 in mitochondrial physiology. Am J Physiol Cell Physiol. 310:C625–C628. 2016. View Article : Google Scholar : PubMed/NCBI
9	Schiattarella GG, Cattaneo F, Pironti G, Magliulo F, Carotenuto G, Pirozzi M, Polishchuk R, Borzacchiello D, Paolillo R, Oliveti M, et al: Akap1 deficiency promotes mitochondrial aberrations and exacerbates cardiac injury following permanent coronary ligation via enhanced mitophagy and apoptosis. PLoS One. 11:e01540762016. View Article : Google Scholar : PubMed/NCBI
10	Smith FD, Langeberg LK and Scott JD: The where's and when's of kinase anchoring. Trends Biochem Sci. 31:316–323. 2006. View Article : Google Scholar : PubMed/NCBI
11	Cardone L, Carlucci A, Affaitati A, Livigni A, DeCristofaro T, Garbi C, Varrone S, Ullrich A, Gottesman ME, Avvedimento EV and Feliciello A: Mitochondrial AKAP121 binds and targets protein tyrosine phosphatase D1, a novel positive regulator of src signaling. Mol Cell Biol. 24:4613–4626. 2004. View Article : Google Scholar : PubMed/NCBI
12	Rinaldi L, Sepe M, Delle Donne R, Conte K, Arcella A, Borzacchiello D, Amente S, De Vita F, Porpora M, Garbi C, et al: Mitochondrial AKAP1 supports mTOR pathway and tumor growth. Cell Death Dis. 8:e28422017. View Article : Google Scholar : PubMed/NCBI
13	Bruix J and Sherman M: Practice Guidelines Committee, American Association for the Study of Liver Diseases: Management of hepatocellular carcinoma. Hepatology. 42:1208–1236. 2005. View Article : Google Scholar : PubMed/NCBI
14	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
15	Starley BQ, Calcagno CJ and Harrison SA: Nonalcoholic fatty liver disease and hepatocellular carcinoma: A weighty connection. Hepatology. 51:1820–1832. 2010. View Article : Google Scholar : PubMed/NCBI
16	El-Serag HB, Tran T and Everhart JE: Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology. 126:460–468. 2004. View Article : Google Scholar : PubMed/NCBI
17	Yang JD, Mohamed HA, Cvinar JL, Gores GJ, Roberts LR and Kim WR: Diabetes mellitus heightens the risk of hepatocellular carcinoma except in patients with hepatitis C cirrhosis. Am J Gastroenterol. 111:1573–1580. 2016. View Article : Google Scholar : PubMed/NCBI
18	Henze K and Martin W: Evolutionary biology: Essence of mitochondria. Nature. 426:127–128. 2003. View Article : Google Scholar : PubMed/NCBI
19	Weinberg SE and Chandel NS: Targeting mitochondria metabolism for cancer therapy. Nat Chem Biol. 11:9–15. 2015. View Article : Google Scholar : PubMed/NCBI
20	Vazquez F, Lim JH, Chim H, Bhalla K, Girnun G, Pierce K, Clish CB, Granter SR, Widlund HR, Spiegelman BM and Puigserver P: PGC1alpha expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress. Cancer Cell. 23:287–301. 2013. View Article : Google Scholar : PubMed/NCBI
21	Genini D, Brambilla L, Laurini E, Merulla J, Civenni G, Pandit S, D'Antuono R, Perez L, Levy DE, Pricl S, et al: Mitochondrial dysfunction induced by a SH2 domain-targeting STAT3 inhibitor leads to metabolic synthetic lethality in cancer cells. Proc Natl Acad Sci USA. 114:E4924–E4933. 2017. View Article : Google Scholar : PubMed/NCBI
22	Yuan D, Huang S, Berger E, Liu L, Gross N, Heinzmann F, Ringelhan M, Connor TO, Stadler M, Meister M, et al: Kupffer cell-derived Tnf triggers cholangiocellular tumorigenesis through JNK due to chronic mitochondrial dysfunction and ROS. Cancer Cell. 31:771–789.e6. 2017. View Article : Google Scholar : PubMed/NCBI
23	Viale A, Pettazzoni P, Lyssiotis CA, Ying H, Sánchez N, Marchesini M, Carugo A, Green T, Seth S, Giuliani V, et al: Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature. 514:628–632. 2014. View Article : Google Scholar : PubMed/NCBI
24	Bruix J, Reig M and Sherman M: Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology. 150:835–853. 2016. View Article : Google Scholar : PubMed/NCBI